Vaccination of Fusion-VAC-XS15

Phase 1Small molecule

Vaccination of Fusion-VAC-XS15 is one of 26 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Hepatocellular CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Preclinical

1 2

Viread

Gilead

Preclinical

1 3

Sovaldi

Gilead

Preclinical

1 4

Coreg

Akero Therapeutics

Preclinical

2 5

Vermox

WWim Janssens

Preclinical

1 6

Opdivo

Bristol-Myers Squibb

Preclinical

2 7

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Statin

1 9

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

5 10

SHR-1210

JJiangsu HengRui Medicine Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Hepatocellular Carcinoma

NCT06789198

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA

Recruiting·UUniversity Hospital Tuebingen·Phase 1·NCT06789198·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vaccination of Fusion-VAC-XS15. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vaccination of Fusion-VAC-XS15 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vaccination of Fusion-VAC-XS15. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Tuebingen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity Hospital Tuebingen

Vaccination of Fusion-VAC-XS15

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News